Navigation Links
New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder

Nausea generally was transient, usually resolving within the first week. Nine patients (9 percent) had hypertension during the trial. Six patients reported a serious adverse event, none of which was considered related to desvenlafaxine succinate. Adverse events were noted as the cause of discontinuation from the study in about one-third of patients -- with the majority of discontinuations occurring in the first week. Study findings also showed that HAM-D17 mean total scores steadily decreased from baseline at Day 7 through Day 60 and continued to decrease through the end of the study.

Poster NR363: Ahmed S, et al. Switch from Venlafaxine to Desvenlafaxine Succinate Is Well-Tolerated in Patients with Major Depressive Disorder

In this study, patients taking venlafaxine ER were able to transition to desvenlafaxine succinate with a lower incidence of nausea than patients who switched from placebo to 200 mg/day of desvenlafaxine succinate. Furthermore, patients who switched from venlafaxine ER to desvenlafaxine succinate and those who remained on desvenlafaxine succinate were less likely to discontinue therapy than patients who switched from placebo to 200 mg/day of desvenlafaxine succinate (without titration).

Before joining the 10-week, open-label study, 517 patients completed one of two eight-week, double-blind, placebo-controlled, flexible-dose studies of desvenlafaxine succinate and venlafaxine ER. Patients who received either placebo (n=186) or venlafaxine ER (n=183) during the double-blind study began the open-label phase at 200 mg/day of desvenlafaxine succinate, while patients who took desvenlafaxine succinate (n=148) during the double-blind study remained on the same dose at the beginning of the open-label study. Based on clinical response, each patient's dose of desvenlafaxine succinate could be adjusted during the open-label study.

Study findings show that overall treatment-emergent adverse events reported during the 10-week study
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:9/2/2015)... 2, 2015 Ascletis announced today the completion ... investment was led by C-Bridge Capital, joined by Tasly ... The valuation of the Company before financing was US$300 ... be used to expand Ascletis, pipeline, strengthen global development ... the support of the investors, Ascletis is now entering ...
(Date:9/2/2015)... 2015  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS ... today that members of its leadership team will be ... , First World Congress on Electroporation ... & Environmental Technologies; Portoroz, Slovenia ... Conference; New York, NY ...
(Date:9/2/2015)... Americord Registry , a private cord blood , ... announced today that is has earned the position of 286 ... http://photos.prnewswire.com/prnh/20150902/263095LOGO To qualify for the top ... over the past three years. Americord submitted growth that measured ... quarterly growth during the first quarter of 2015 and 30% ...
Breaking Medicine Technology:Ascletis Secures US$35 Million Financing 2Ascletis Secures US$35 Million Financing 3OncoSec to Present at Scientific and Investment Conferences in September 2OncoSec to Present at Scientific and Investment Conferences in September 3OncoSec to Present at Scientific and Investment Conferences in September 4OncoSec to Present at Scientific and Investment Conferences in September 5Americord Registry Announces Ranking on 2015 Inc. 500 2
... , a Rye, New York-based drug research and development ... randomized placebo controlled multicenter clinical trial of CM-AT for ... compared CM-AT to placebo in children with autism aged ... significant effect of CM-AT over placebo on both core ...
... England, December 7, 2011 Hosted IT Environment ... Clinics and Walk-in Centres Across the UK A ... across the UK, has outsourced its IT infrastructure to Cloud ... care. Contracted by the NHS, The Practice started ...
Cached Medicine Technology:Curemark LLC Reports Positive Phase III Results of CM-AT in Children With Autism 2Curemark LLC Reports Positive Phase III Results of CM-AT in Children With Autism 3NHS Contractor Outsources IT to Focus on Delivering Patient Care 2NHS Contractor Outsources IT to Focus on Delivering Patient Care 3
(Date:9/2/2015)... ... ... Every year at this time, students prepare to go back to school. ... the academic workload confronting them. They just don’t have the skills needed to do ... students how to study. , “Bankers bank. Salesmen sell. Teachers teach. The job of ...
(Date:9/2/2015)... ... September 02, 2015 , ... Amada Senior Care, premier provider ... Kansas – its Johnson County location. Amada franchise partners Mike and Mell ... registered nurse background and spent over 20 years in medical device sales while Mell ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... Fort Lauderdale, CENTURION SERVICE GROUP is internationally known as an industry leader specializing ... house in the world, selling more than 100,000 pieces of medical equipment every ...
(Date:9/2/2015)... Utah (PRWEB) , ... September 02, 2015 , ... On ... Utah to attend doTERRA’s annual convention, the largest single-company convention to date for the ... Advocates and look forward to a tremendous event,” states David Stirling, doTERRA CEO. “One ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... pioneer in marine cosmetics introduces PIONNIÈRE XMF Perfection Youth Rich Cream , ... combines breakthrough biotechnological anti-aging power with a lipid-replenishing marine oil for intense nourishing ...
Breaking Medicine News(10 mins):Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 2Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 3Health News:Amada Senior Care Expands to Greater Kansas City 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 3Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 2Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 3Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 4
... venom of the brown recluse spider, researchers at the University ... to open// molecular pores, called ion channels, in the membrane ... Lu, MD, PhD; Yajamana Ramu, PhD; and Yanping Xu, MD, ... venoms from over 100 poisonous invertebrate species to make this ...
... today launched a new vision correction technology, Zyoptix Aspheric, ... ,"There are 60 clinics all across India which use ... be upgraded to Zyoptix Aspherix which further reduces post ... and Lomb India Director-Surgical business Rajat Goel told reporters ...
... like corks to block oxygen flow to tumors, or to ... to a tumor is called embolization, and using gas bubbles ... promising is that the technique allows doctors to control exactly ... to surrounding tissue is minimal, said Joseph Bull, assistant professor ...
... by Dr. Adam Godzik at the Burnham Institute for ... understanding of information gathered// from the human genome project. ... a three year period, this consortium, under the name ... adequate support to scientists from Burnham and UCSD's Computer ...
... labs of Yale Goldman, MD, PhD, Director of the ... of Medicine,// and Erika Holzbaur, PhD, Professor of Physiology, ... show proteins that function as molecular motors are surprisingly ... cell. These observations could lead to better ways to ...
... Once a month osteoporisis drug and extra telephone support from ... among women for their drug treatment// than those who took ... issue of IJCP, the International Journal of Clinical Practice. ... part in the PERSIST study between January 2005 and January ...
Cached Medicine News:Health News:New Way to Open Cellular Ion Channels, Implications for Drug Design 2Health News:Researchers Use Bubbles in Cancer Treatment and Drug Delivery 2Health News:Joint Center for Molecular Modeling Instituted by Burnham Institute for Medical Research & UC San Diego 2Health News:Discovery of Agile Molecular Motors Could Aid in Treating Motor Neuron Diseases 2Health News:Women More Persistent with Monthly Osteoporosis Treatment 2
... The Stryker Cross-Screw System ... and secure method for ACL ... The Stryker Cross-Screw System provides ... fixation. The implant comes in ...
... Universal Wedge Screw is a ... cruciate reconstruction and is indicated ... grafts. The Universal Wedge Screw ... has blunt threads which protect ...
... The Stryker Threaded ... surgeon yet another choice ... tunnel. Dilators provide compaction ... The compaction of bone ...
... The Stryker Conquest Suture ... instruments that pierce through ... suture through the tissue ... The Conquest Retrievers are ...
Medicine Products: